Jade Biosciences filings document a Nasdaq-listed clinical-stage biotechnology issuer developing antibody therapies for autoimmune diseases. Form 8-K reports furnish operating and financial results and attach corporate updates covering JADE101, JADE201, JADE301, research progress, and liquidity-related disclosures.
The company's proxy and material-event filings cover annual meeting matters, board and officer changes, compensatory arrangements, employment inducement stock plans, material agreements, private placement securities, common stock and pre-funded warrant terms, and other capital-structure disclosures. The filings also identify Jade as an emerging growth company with common stock registered under the Exchange Act.
Bellevue Group AG, through its wholly owned subsidiary Bellevue Asset Management AG, reported a significant passive ownership stake in Jade Biosciences, Inc. common stock. They beneficially own 3,341,103 shares, representing 6.8% of the outstanding common stock, with shared voting and dispositive power over all of these shares.
The filing states that the securities were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing control of Jade Biosciences. Bellevue and its subsidiary certify that the information provided is true, complete, and correct.
Janus Henderson Group plc filed a Schedule 13G reporting a passive ownership stake in Jade Biosciences, Inc. common stock. Through its investment adviser subsidiaries managing various client accounts, it is deemed the beneficial owner of 3,063,457 shares, representing 6.2% of the class.
These shares are held with shared voting and dispositive power, while Janus Henderson’s asset managers exercise investment and voting discretion for client portfolios. The managed portfolios retain rights to dividends and sale proceeds. Janus Henderson certifies the holdings are in the ordinary course of business and not intended to change or influence control of Jade Biosciences.
Jade Biosciences Chief Financial Officer Bradford D. Dahms received new equity awards on February 12, 2026. He was granted 37,813 shares of common stock in the form of restricted stock units at no cash cost, each representing a right to one share.
These RSUs vest in four equal installments on each of the first four anniversaries of February 15, 2026, contingent on continued service. Dahms was also granted stock options for 226,875 shares of common stock with a $14.81 exercise price, granted at no cost.
One quarter of the options vest on February 15, 2027, with the remaining three quarters vesting in equal monthly installments over the following three years, also subject to his continued service. All reported holdings are shown as directly owned.
Jade Biosciences, Inc. granted equity awards to Chief Legal Officer and Corporate Secretary Elizabeth Balta. On February 12, 2026, she received 28,125 shares of common stock in the form of restricted stock units at $0 per share and a stock option for 168,750 shares with a $14.81 exercise price.
The RSUs vest in four equal parts on each of the first four anniversaries of February 15, 2026, if she remains in service. The option vests 25% on February 15, 2027, with the remaining 75% vesting in equal monthly installments over the following three years, also contingent on continued service.
Frohlich Tom reported acquisition or exercise transactions in a Form 4 filing for JBIO. The filing lists transactions totaling 551,250 shares. Following the reported transactions, holdings were 472,500 shares.
Jade Biosciences, Inc. officer Andrew James King reported equity compensation awards that increase his stake in the company. On February 12, 2026, he received 41,250 shares of common stock as a grant priced at $0 per share, bringing his directly owned common shares to 386,113.
He was also granted a stock option for 247,500 shares at an exercise price of $14.81 per share, expiring on February 11, 2036, with 247,500 derivative securities owned after the grant. The 41,250-share common stock grant is in the form of restricted stock units, vesting in four equal annual installments starting on February 15, 2026. The option vests 25% on February 15, 2027, with the remaining 75% vesting in equal monthly installments over the following three years, all subject to his continued service.
Deep Track Capital and related investors now report no beneficial ownership of Jade Biosciences, Inc. common stock. As of the event date of December 31, 2025, Deep Track Capital, Deep Track Biotechnology Master Fund, Ltd., and David Kroin each report 0 shares beneficially owned, representing 0.00% of the common stock.
The ownership calculations use 46,004,205 common shares outstanding as of November 7, 2025, as disclosed in Jade Biosciences’ prior quarterly report. The filing confirms that the securities referenced were not acquired or held for the purpose of changing or influencing control of Jade Biosciences.
The Vanguard Group filed an amended Schedule 13G reporting passive ownership of Jade Biosciences Inc common stock. Vanguard reports beneficial ownership of 2,095,767 shares, representing 4.24% of the outstanding common stock as of 12/31/2025.
Vanguard has shared voting power over 170,125 shares and shared dispositive power over 2,095,767 shares, with no sole voting or dispositive power. The filing notes an internal realignment effective January 12, 2026, after which certain Vanguard subsidiaries or business divisions are expected to report beneficial ownership separately while continuing the same investment strategies.
Jade Biosciences, Inc. entered into a securities purchase agreement for a private placement of 3,214,286 shares of common stock at $14.00 per share, for expected gross proceeds of approximately $45 million before expenses. The closing is expected on December 16, 2025, subject to customary closing conditions and in accordance with applicable Nasdaq rules.
The company plans to use the net proceeds to fund research and development, as well as general corporate expenses and working capital needs, supporting ongoing operations and pipeline development.
Jade also entered into a Registration Rights Agreement with the purchaser, committing to file a registration statement (or amend an existing one) to register the resale of the shares within 45 days after closing and to seek effectiveness within 75 days, with specified penalties if these timelines are not met. The private placement relies on exemptions from registration under Section 4(a)(2) and/or Rule 506 of Regulation D, with the investor represented as an accredited investor or qualified institutional buyer and the securities sold without general solicitation.